Metraipolis › archive › dc_f4398dd15df2

Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report — Europe PMC PMID:42180063

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42180063
DOI
10.3389/fonc.2026.1699804
License (as archived)
solo-consultazione
Archived
2026-11-02T14:56:57.751Z
SHA-256 of the archived text
bfd88b74bd141552674f80e83a88dc91b4e8f7342869a6a7b1e331316164c7de
Stable URL of this page
https://metraipolis.com/documento/dc_f4398dd15df2

How to cite

Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report — Europe PMC PMID:42180063 — Europe PMC (en), https://europepmc.org/article/MED/42180063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f4398dd15df2 (Metraipolis archive dc_f4398dd15df2, sha256 bfd88b74bd141552674f80e83a88dc91b4e8f7342869a6a7b1e331316164c7de)
BibTeX
@misc{dcf4398dd15df2,
  title = {Sequential almonertinib therapy following osimertinib-induced interstitial lung disease in early-stage EGFR-mutant lung adenocarcinoma: a case report — Europe PMC PMID:42180063},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42180063},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f4398dd15df2; sha256 bfd88b74bd141552674f80e83a88dc91b4e8f7342869a6a7b1e331316164c7de},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42180063. Agents can read the archived copy with the MCP tool read_document.